Tumour-absorbed dose and efficacy of peptide receptor radionuclide therapy with [90Y]Y-DOTATOC in patients with refractory meningioma: a single-centre experience

放射性核素治疗 医学 累积剂量 耐火材料(行星科学) 核医学 肽受体 放射治疗 放射科 生长抑素 内科学 生长抑素受体 外照射放疗 外科 剂量学 回顾性队列研究 立体定向放射治疗 肿瘤科 全身疗法 无线电技术 放射治疗计划 治疗指标 癌症 脑膜瘤 泌尿科 化疗 毒性 有效剂量(辐射) 靶向治疗 磁共振成像 剂量分馏 队列 治疗效果 切除术
作者
Lilit Schweiger,Giulia Santo,Ariane Kronthaler,Gianpaolo di Santo,Sarah Iglseder,Stephanie Mangesius,Julian Mangesius,Katharina Stock,Irene Johanna Virgolini
出处
期刊:European Journal of Nuclear Medicine and Molecular Imaging [Springer Science+Business Media]
卷期号:53 (13): 8139-8148
标识
DOI:10.1007/s00259-026-08113-9
摘要

Abstract Aim: The management of treatment-refractory meningioma in patients with previous surgical resection and radiation therapy remains challenging due to the lack of effective systemic treatment options. Therefore, novel therapeutic applications, such as peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors, may offer a promising therapeutic strategy. We aimed to assess the lesion-based tumour-absorbed dose and efficacy of PRRT with [ 90 Y]Y-DOTATOC in patients with treatment-refractory meningioma. Materials and methods: In this study, 10 patients with therapy-refractory meningioma were retrospectively included. All patients received systemic [ 90 Y]Y-DOTATOC therapy following prior surgical resection and radiation therapy. In total, 21 lesions were assessed morphologically by contrast-enhanced MRI and [ 68 Ga]Ga-DOTATOC PET/CT both before and after therapy. All patients underwent dosimetry with [ 111 In]In-DOTATOC prior to [ 90 Y]Y-DOTATOC therapy. Treatment response was evaluated according to RANO bidimensional and volumetric criteria. Overall survival (OS) was defined from the first PRRT cycle until death. Results: The median cumulative activity administered per patient was 3804 MBq (IQR, 3140–4050 MBq), with a median of 3 cycles (range: 1–7). On lesion-based analysis following PRRT, response assessment was available in 19/21 (91.5%) lesions. Among these, tumour stabilisation according to RANO criteria was observed in 7/19 (36.8%) lesions, with a median cumulative tumour-absorbed dose of 52.7 Gy. Morphological tumour progression was noted in 12/19 (63.2%) lesions, with a median cumulative tumour-absorbed dose of 43.8 Gy. The difference in tumour-absorbed doses between morphologically stable and progressive lesions according to RANO criteria was not statistically significant ( P = 0.82). Values for SUVmax and SUVmean from pretherapeutic [ 68 Ga]Ga-DOTATOC PET/CT significantly correlated with the tumour-absorbed doses ( P = 0.018 for SUVmax, P = 0.021 for SUVmean, respectively). Post-therapeutic [ 68 Ga]Ga-DOTATOC PET/CT demonstrated an increase in SUVmax in 19/21 (90.5%) lesions (median: 40.8%, range: 13.0% − 101.2%). The median OS in the whole cohort was 23.0 months (95% CI 12.5–33.5 months). Conclusion: Our preliminary results indicate no significant difference in tumour-absorbed doses between morphologically stable lesions and those with progressive disease, as defined by the RANO criteria. However, lesion-based analysis revealed a significant correlation between pretherapeutic [ 68 Ga]Ga-DOTATOC PET/CT uptake and tumour-absorbed doses following [ 90 Y]Y-DOTATOC therapy. These findings suggest that baseline PET/CT may serve as a valuable tool for estimating cumulative tumour-absorbed dose and guiding the optimal cumulative activity of PRRT.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一个爱打乒乓球的彪完成签到 ,获得积分10
1秒前
Canmiyo完成签到 ,获得积分10
2秒前
John完成签到,获得积分10
4秒前
molihuakai的应助被369ninja采纳,获得10
5秒前
5秒前
蓝天完成签到 ,获得积分10
9秒前
Owen的应助被科研通管家采纳,获得10
9秒前
心想事成完成签到 ,获得积分10
9秒前
歪歪发布了新的文献求助10
11秒前
风中睫毛完成签到,获得积分10
12秒前
雪山大地发布了新的文献求助10
16秒前
ahoshuo完成签到,获得积分10
17秒前
陈炳蓉完成签到,获得积分10
19秒前
研友_VZG7GZ的应助被369ninja采纳,获得10
20秒前
复杂妙海完成签到,获得积分10
22秒前
中華人民共和完成签到,获得积分10
23秒前
23秒前
科研通AI6.4的应助被Firsterchao采纳,获得30
23秒前
小蘑菇的应助被歪歪采纳,获得10
28秒前
旺旺完成签到,获得积分10
29秒前
Chen116完成签到,获得积分10
30秒前
哎呀呀喂完成签到,获得积分10
32秒前
生动幼菱发布了新的文献求助10
32秒前
英姑的应助被369ninja采纳,获得10
35秒前
leo完成签到,获得积分10
36秒前
37秒前
pei完成签到 ,获得积分10
38秒前
Murphy完成签到 ,获得积分10
39秒前
雪山大地发布了新的文献求助10
40秒前
科研通AI6.4的应助被Jasmine采纳,获得10
41秒前
369ninja发布了新的文献求助10
42秒前
背后隶完成签到,获得积分10
43秒前
真水无香123完成签到,获得积分10
46秒前
贤惠的忆南完成签到 ,获得积分10
47秒前
49秒前
一九完成签到 ,获得积分10
50秒前
nanwang完成签到,获得积分10
50秒前
yurunxintian完成签到,获得积分10
50秒前
maclogos完成签到,获得积分10
50秒前
帅气的笑容完成签到 ,获得积分10
53秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166538
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750645
捐赠科研通 7757337
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553521
邀请新用户注册赠送积分活动 2473904